DexCom (DXCM) vs ResMed (RMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
DexCom (DXCM) has outperformed ResMed (RMD) over the past year, gaining 27.7% versus a loss of 20.2%. Over five years, RMD leads with a -11.6% price change compared with -38.1% for DXCM. ResMed is the larger company by market cap ($31.74 billion vs $31.73 billion), about 1.0 times the size, while DexCom is growing revenue faster (+15.6% vs +9.9%).
On valuation, ResMed trades at a lower forward P/E (17.1x vs 26.9x for DexCom). ResMed pays a dividend yielding 1.06%, while DexCom does not currently pay one. ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 17.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | RMD |
|---|---|---|
| Share price | $84.09 | $225.70 |
| Market cap | $31.73B | $31.74B |
| 1-day change | -0.25% | -0.13% |
| YTD return | +27.02% | -6.18% |
| 1-year return | +27.67% | -20.23% |
| 5-year return | -38.07% | -11.55% |
| P/E ratio (TTM) | 33.37 | 21.64 |
| Forward P/E | 26.89 | 17.06 |
| EPS (TTM) | $2.52 | $10.43 |
| Dividend yield | 0.00% | 1.06% |
| Annual dividend | $0.00 | $2.40 |
| Revenue (latest FY) | $4.66B | $5.65B |
| Revenue growth (YoY) | +15.60% | +9.85% |
| Net income (latest FY) | $836.30M | $1.52B |
| Gross margin | 60.10% | 61.06% |
| Operating margin | 19.56% | 33.37% |
| Net margin | 17.94% | 26.94% |
| 52-week high | $92.59 | $284.05 |
| 52-week low | $54.11 | $180.27 |
| Distance from 52-week high | -9.18% | -20.54% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +14.44% | +10.87% |
| Average volume | 4.44M | 1.34M |
| Shares outstanding | 377.36M | 140.64M |
| Employees | 11,000 | 11,370 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DXCM has outperformed RMD by 47.9 percentage points over the past year.
- DexCom trades at a higher earnings multiple (33.4x vs 21.6x trailing P/E).
- ResMed offers a meaningfully higher dividend yield (1.06% vs 0.00%).
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 17.9 cents for DexCom.
- DexCom grew revenue faster in its latest fiscal year (+15.60% vs +9.85%).
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Health Care · Medical/Dental Instruments · 11,000 employees
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
DXCM vs RMD FAQ
Which is bigger, DexCom or ResMed?
ResMed (RMD) is larger, with a market capitalization of $31.74B compared with $31.73B for DexCom (DXCM).
Which stock has performed better over the past year, DXCM or RMD?
DXCM returned +27.67% over the past 12 months, compared with -20.23% for RMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXCM or RMD?
RMD has the lower trailing P/E at 21.6, versus 33.4 for DXCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, DexCom or ResMed?
ResMed pays a dividend yielding 1.06%, while DexCom does not currently pay a regular dividend.
Are DexCom and ResMed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.